Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGNYZ) Goodwill (2016 - 2025)

Historic Goodwill for Ligand Pharmaceuticals (LGNYZ) over the last 16 years, with Q3 2025 value amounting to $101.5 million.

  • Ligand Pharmaceuticals' Goodwill fell 352.4% to $101.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $101.5 million, marking a year-over-year decrease of 352.4%. This contributed to the annual value of $105.2 million for FY2024, which is 181.87% up from last year.
  • Ligand Pharmaceuticals' Goodwill amounted to $101.5 million in Q3 2025, which was down 352.4% from $101.5 million recorded in Q2 2025.
  • In the past 5 years, Ligand Pharmaceuticals' Goodwill ranged from a high of $190.5 million in Q2 2021 and a low of $3.7 million during Q3 2023
  • Its 5-year average for Goodwill is $118.9 million, with a median of $105.2 million in 2024.
  • Its Goodwill has fluctuated over the past 5 years, first plummeted by 4451.88% in 2022, then surged by 273769.21% in 2024.
  • Over the past 5 years, Ligand Pharmaceuticals' Goodwill (Quarter) stood at $190.2 million in 2021, then fell by 4.72% to $181.2 million in 2022, then crashed by 42.95% to $103.4 million in 2023, then grew by 1.82% to $105.2 million in 2024, then dropped by 3.52% to $101.5 million in 2025.
  • Its last three reported values are $101.5 million in Q3 2025, $101.5 million for Q2 2025, and $101.5 million during Q1 2025.